LABT (Lakewood-Amedex Biotherapeutics) Non Operating Income: $0.00 Mil (TTM As of Mar. 2026)


LABT Lakewood-Amedex Biotherapeutics Inc LABT
8 GF Score
Price $3.55
View Full Analysis

What is Lakewood-Amedex Biotherapeutics Non Operating Income?

Lakewood-Amedex Biotherapeutics LABT +2.33% 8 Non Operating Income is $0.00 Mil as of Mar. 2026. GuruFocus rates LABT with a GF Score™ of 8/100.

Non Operating Income is income or expense that comes from miscellaneous sources. Lakewood-Amedex Biotherapeutics's Non Operating Income for the three months ended in Mar. 2026 was $0.00 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Lakewood-Amedex Biotherapeutics Non Operating Income Related Terms

Lakewood-Amedex Biotherapeutics Non Operating Income Historical Data

* Premium members only.

The historical data trend for Lakewood-Amedex Biotherapeutics's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakewood-Amedex Biotherapeutics Non Operating Income Chart

Lakewood-Amedex Biotherapeutics Annual Data
Trend Dec23 Dec24 Dec25
Non Operating Income
0.01 -0.97 0.00

Lakewood-Amedex Biotherapeutics Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Non Operating Income Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
LABT
8GF Score
Lakewood-Amedex Biotherapeutics Inc LABT
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakewood-Amedex Biotherapeutics Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $0.00 Mil mean?
Lakewood-Amedex Biotherapeutics (LABT) has a Non Operating Income of $0.00 Mil as of Mar. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Lakewood-Amedex Biotherapeutics and its competitors.
Is Lakewood-Amedex Biotherapeutics' Non Operating Income too high?
Lakewood-Amedex Biotherapeutics' current Non Operating Income is $0.00 Mil. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Non Operating Income compare to CURX and PBM?
Lakewood-Amedex Biotherapeutics' Non Operating Income of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. Lakewood-Amedex Biotherapeutics's current Non Operating Income is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Non Operating Income of $0.00 Mil. The current Non Operating Income is $0.00 Mil. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Non Operating Income is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lakewood-Amedex Biotherapeutics Business Description

Address 8031 Cooper Creek Blvd, Unit 103, University Park, FL, USA, 34201
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score

Get the complete analysis for LABT

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price